Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program

Olivia M. Dong; Jill Bates; Catherine Chanfreau-Coffinier; Michael Naglich; Michael J. Kelley; Laurence J. Meyer; Michael Icardi; Jason L. Vassy; Peruvemba Sriram; Craig William Heise; Salvador Rivas; Maria Ribeiro; Russell Jacobitz; Susan Rozelle; Jennifer G. Chapman; Deepak Voora

doi:10.2217/pgs-2020-0173

Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program

Olivia M. Dong, Jill Bates, Catherine Chanfreau-Coffinier, Michael Naglich, Michael J. Kelley, Laurence J. Meyer, Michael Icardi, Jason L. Vassy, Peruvemba Sriram, Craig William Heise, Salvador Rivas, Maria Ribeiro, Russell Jacobitz, Susan Rozelle, Jennifer G. Chapman, Deepak Voora

Internal Medicine, Phoenix

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

Original language	English (US)
Pages (from-to)	137-144
Number of pages	8
Journal	Pharmacogenomics
Volume	22
Issue number	3
DOIs	https://doi.org/10.2217/pgs-2020-0173
State	Published - Feb 2021

Keywords

Veterans Affairs
clinical program
pharmacogenetics
pharmacogenomics
precision medicine
veterans

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2020-0173

Cite this

Dong, O. M., Bates, J., Chanfreau-Coffinier, C., Naglich, M., Kelley, M. J., Meyer, L. J., Icardi, M., Vassy, J. L., Sriram, P., Heise, C. W., Rivas, S., Ribeiro, M., Jacobitz, R., Rozelle, S., Chapman, J. G., & Voora, D. (2021). Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program. Pharmacogenomics, 22(3), 137-144. https://doi.org/10.2217/pgs-2020-0173

@article{376f7135f24a4ccb8ae942a55a95f708,

title = "Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program",

abstract = "In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.",

keywords = "Veterans Affairs, clinical program, pharmacogenetics, pharmacogenomics, precision medicine, veterans",

author = "Dong, {Olivia M.} and Jill Bates and Catherine Chanfreau-Coffinier and Michael Naglich and Kelley, {Michael J.} and Meyer, {Laurence J.} and Michael Icardi and Vassy, {Jason L.} and Peruvemba Sriram and Heise, {Craig William} and Salvador Rivas and Maria Ribeiro and Russell Jacobitz and Susan Rozelle and Chapman, {Jennifer G.} and Deepak Voora",

year = "2021",

month = feb,

doi = "10.2217/pgs-2020-0173",

language = "English (US)",

volume = "22",

pages = "137--144",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program

AU - Dong, Olivia M.

AU - Bates, Jill

AU - Chanfreau-Coffinier, Catherine

AU - Naglich, Michael

AU - Kelley, Michael J.

AU - Meyer, Laurence J.

AU - Icardi, Michael

AU - Vassy, Jason L.

AU - Sriram, Peruvemba

AU - Heise, Craig William

AU - Rivas, Salvador

AU - Ribeiro, Maria

AU - Jacobitz, Russell

AU - Rozelle, Susan

AU - Chapman, Jennifer G.

AU - Voora, Deepak

PY - 2021/2

Y1 - 2021/2

N2 - In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

AB - In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

KW - Veterans Affairs

KW - clinical program

KW - pharmacogenetics

KW - pharmacogenomics

KW - precision medicine

KW - veterans

UR - http://www.scopus.com/inward/record.url?scp=85101668954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101668954&partnerID=8YFLogxK

U2 - 10.2217/pgs-2020-0173

DO - 10.2217/pgs-2020-0173

M3 - Article

C2 - 33403869

AN - SCOPUS:85101668954

SN - 1462-2416

VL - 22

SP - 137

EP - 144

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 3

ER -

Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this